Takita, Mumon
Yoshida, Toru
Tsuchida, Tomoya
Nakagama, Yu
Kido, Yasutoshi
Suzuki, Shotaro
Imamura, Mitsuru
Kawahata, Kimito
Shimizu, Goji
Yoshida, Hideki
Morikawa, Daiki
Kawaguchi, Takeshi
Fujii, Shuichi
Tsukuda, Jumpei
Motohashi, Takako
Fujitani, Shigeki
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20jk0110021, JP20he1122001)
Article History
Received: 17 August 2021
Accepted: 17 May 2022
First Online: 1 June 2022
Competing interests
: YK and YN report ownership of equity of Quantum Molecular Diagnostics, an Osaka City University spinout. Quantum Molecular Diagnostics targets infectious diseases to develop and provide innovative diagnostics and is engaged in the codevelopment of the serological assay along with Mokobio Biotechnology R&D, USA. YK and YN also report receiving financial support from Abbott Japan LLC, Japan. The other authors declare that there are no conflict of interests.